🇺🇸 FDA

P1 · Therapeutic area intelligence

Obesity & metabolic patent intelligence

GLP-1, GIP/GLP-1, diabetes, and metabolic disease patents — critical for obesity market IP tracking.

Patents
276

Quick answer

276 US pharmaceutical patents in our index match Obesity & metabolic title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12421317

    Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12421282

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12397058

    Metabolically stable prodrugs

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12383554

    Compositions and methods to protect mammalian tissue against cold and other metabolic stresses

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12364693

    Methods of treating metabolic diseases with fused bicyclic pyrazoles

    Belite Bio, Inc · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12329816

    Immunotherapy with metabolic enzyme expression

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12318426

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12291530

    GLP-1R agonist and therapeutic method thereof

    Ascletis Pharma (China) Co., Limited · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12280124

    Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12280093

    Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12280029

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12252522

    Myokines for treating cell proliferative and metabolic diseases and disorders

    Northwestern University · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12241902

    Probes for detection of copper

    The Regents of the University of California · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12234236

    GLP-1R agonist and therapeutic method thereof

    Ascletis Pharma (China) Co., Limited · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12215133

    GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

    BrightGene Bio-Medical Technology Co., Ltd. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12202798

    Antimicrobial compounds, compositions, and articles of manufacture for selectively inhibiting pathogenic microbes

    The Board of Regents of the University of Oklahoma · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12201617

    HDAC6 inhibitors for treatment of metabolic disease and HFpEF

    Tenaya Therapeutics, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12201601

    Treatment for obesity

    AXSOME MALTA LTD. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12194065

    Methods and compositions to enhance metabolic detoxification systems

    Nature's Sunshine Products, Inc. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12174205

    Phosphatidylethanolamine-specific probes

    Northwestern University · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12145974

    Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12115225

    GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12084515

    Compositions and methods for treatment of diabetic macular edema

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12029782

    MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof

    Cue Biopharma, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11957704

    Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11925649

    Treatments for diabetic neuropathy

    The Regents of the University of California · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11872355

    Medical device for detecting fluid parameters using fluorescent probes

    Covidien LP · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11872200

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11834640

    Device and uses thereof for treating diabetes

    The Board of Regents of the University of Texas System · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11759476

    Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11744873

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11723990

    Library of pH responsive polymers and nanoprobes thereof

    The Board of Regents of the University of Texas System · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11690851

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11684596

    Antidiabetic pharmaceutical compositions and preparation method thereof

    Elite Pharmaceutical Solution Inc. · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11684626

    Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11642354

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11623010

    Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition and methods for treatment

    BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD. · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11497725

    Treatment for obesity

    AXSOME MALTA LTD. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11490643

    Lactobacillus casei for treating obesity and associated metabolic disorders

    PrecisionBiotics Group Limited · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11439635

    B cell lymphoma 6 protein (BCL6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

    Northwestern University · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11419883

    Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes

    The Regents of the University of California · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11400066

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11395848

    Methods and compositions for treating diabetes

    Oramed Ltd. · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11389444

    Methods of treating metabolic diseases with fused bicyclic pyrazoles

    Belite Bio, Inc · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11389449

    Treatment of metabolic syndrome with an sGC stimulator

    Cyclerion Therapeutics, Inc. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11357777

    Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)

    Cyclerion Therapeutics, Inc. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11359246

    Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Obesity & metabolic patents are indexed?

276 patents match our Obesity & metabolic classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.